Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Lentz

Showing results (81-90 of 106) with videos related to

Pageof 11
Sort By:
Chemistry & Biology|February 27, 2013
A selective inhibitor of heme biosynthesis in endosymbiotic bacteria elicits antifilarial activity in vitroChristian S Lentz, Victoria Halls, Jeffrey S Hannam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2003
Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group StudyHolly H Gallion, Virginia L Brunetto, Michael Cibull, et al.
Gynecologic Oncology|November 7, 2000
A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group StudyG Sutton, V L Brunetto, L Kilgore, et al.
Nature Chemical Biology|May 18, 2018
Identification of a S. aureus virulence factor by activity-based protein profiling (ABPP)Christian S Lentz, Jessica R Sheldon, Lisa A Crawford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group studyRobert C Young, Mark F Brady, Roberta K Nieberg, et al.
Gynecologic Oncology|June 27, 2026
A second chance for the second look: Feasibility of laparoscopic HIPEC at the conclusion of upfront treatment for epithelial ovarian cancerAna Kouri, Anya Menzies, Kristen Stearns, et al.
Plant Signaling & Behavior|November 22, 2011
Auxin-induced leaf blade expansion in Arabidopsis requires both wounding and detachmentChristopher P Keller, Morgan L Grundstad, Michael A Evanoff, et al.
Gynecologic Oncology|April 19, 2011
A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group studyRobert L Coleman, William E Brady, D Scott McMeekin, et al.
Journal of Medicinal Chemistry|February 27, 2014
wALADin benzimidazoles differentially modulate the function of porphobilinogen synthase orthologsChristian S Lentz, Victoria S Halls, Jeffrey S Hannam, et al.
Gynecologic Oncology|December 21, 2010
A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q)Thomas J Herzog, Michael W Sill, Joan L Walker, et al.
Pageof 11

Showing results (81-90 of 106) with videos related to

Sort By:
Pageof 11
Chemistry & Biology|February 27, 2013
A selective inhibitor of heme biosynthesis in endosymbiotic bacteria elicits antifilarial activity in vitroChristian S Lentz, Victoria Halls, Jeffrey S Hannam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2003
Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group StudyHolly H Gallion, Virginia L Brunetto, Michael Cibull, et al.
Gynecologic Oncology|November 7, 2000
A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group StudyG Sutton, V L Brunetto, L Kilgore, et al.
Nature Chemical Biology|May 18, 2018
Identification of a S. aureus virulence factor by activity-based protein profiling (ABPP)Christian S Lentz, Jessica R Sheldon, Lisa A Crawford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group studyRobert C Young, Mark F Brady, Roberta K Nieberg, et al.
Gynecologic Oncology|June 27, 2026
A second chance for the second look: Feasibility of laparoscopic HIPEC at the conclusion of upfront treatment for epithelial ovarian cancerAna Kouri, Anya Menzies, Kristen Stearns, et al.
Plant Signaling & Behavior|November 22, 2011
Auxin-induced leaf blade expansion in Arabidopsis requires both wounding and detachmentChristopher P Keller, Morgan L Grundstad, Michael A Evanoff, et al.
Gynecologic Oncology|April 19, 2011
A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group studyRobert L Coleman, William E Brady, D Scott McMeekin, et al.
Journal of Medicinal Chemistry|February 27, 2014
wALADin benzimidazoles differentially modulate the function of porphobilinogen synthase orthologsChristian S Lentz, Victoria S Halls, Jeffrey S Hannam, et al.
Gynecologic Oncology|December 21, 2010
A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q)Thomas J Herzog, Michael W Sill, Joan L Walker, et al.
Pageof 11